Akumin Inc. AKU
We take great care to ensure that the data presented and summarized in this overview for AKUMIN INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in AKU
Top Purchases
Top Sells
About AKU
Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures through a network of approximately 200 owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to approximately 1,000 hospitals and health systems across 46 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.
Insider Transactions at AKU
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 15
2023
|
Krishna Kumar President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+50.0%
|
-
|
|
Apr 07
2023
|
John R. Wagner Director |
BUY
Grant, award, or other acquisition
|
Direct |
102,459
+24.48%
|
-
|
|
Apr 07
2023
|
Paul S Viviano Director |
BUY
Grant, award, or other acquisition
|
Direct |
102,459
+32.11%
|
-
|
|
Apr 07
2023
|
Haichen Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
102,459
+32.11%
|
-
|
|
Apr 07
2023
|
Riadh Zine Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
700,000
+9.95%
|
-
|
|
Apr 07
2023
|
R. David Kretschmer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+25.78%
|
-
|
|
Apr 07
2023
|
James Harold Webb Director |
BUY
Grant, award, or other acquisition
|
Direct |
102,459
+28.71%
|
-
|
|
Apr 07
2023
|
Murray Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
102,459
+19.26%
|
-
|
|
Apr 07
2023
|
Stanley G Dunford Director |
BUY
Grant, award, or other acquisition
|
Direct |
102,459
+28.76%
|
-
|
|
Apr 07
2023
|
Rohit Navani Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+12.12%
|
-
|
|
Apr 07
2023
|
Thomas Davies Director |
BUY
Grant, award, or other acquisition
|
Direct |
102,459
+20.21%
|
-
|
|
Mar 31
2023
|
James Wyper Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
57,078
-50.0%
|
-
|
|
Feb 16
2023
|
R. David Kretschmer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+47.01%
|
-
|
|
Jan 01
2023
|
Lawrence Ross Sinclair Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Dec 08
2022
|
Thomas Davies Director |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+33.19%
|
$0
$0.5 P/Share
|
|
Aug 30
2022
|
R. David Kretschmer Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,338
+14.36%
|
$5,338
$1.33 P/Share
|
|
Aug 29
2022
|
R. David Kretschmer Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
6,500
+19.7%
|
$6,500
$1.38 P/Share
|
|
Aug 19
2022
|
R. David Kretschmer Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+11.11%
|
$2,500
$1.07 P/Share
|
|
Aug 18
2022
|
R. David Kretschmer Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
17,500
+29.17%
|
$17,500
$1.13 P/Share
|
|
Aug 18
2022
|
Murray Lee Director |
BUY
Open market or private purchase
|
Indirect |
1,000
+15.38%
|
$1,000
$1.43 P/Share
|